Search research articles
Contact Us
Filters
Showing results (61-70 of 109) with videos related to
Page
of 11
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma
Pavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2012
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts
Gaspar J Kitange, Ann C Mladek, Brett L Carlson, et al.
Journal of Neuro-Oncology
|
November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
Gaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
Molecular Cancer Therapeutics
|
January 29, 2009
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J Clarke, Evan A Mulligan, Patrick T Grogan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 4, 2015
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
Khoan Vu, Shivaprasad Manjappa, John F DiPersio, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 19, 2016
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
Ramzi Abboud, Jesse Keller, Michael Slade, et al.
Blood
|
March 12, 2020
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia, Miguel-Angel Perales, Mark A Schroeder, et al.
Neuro-Oncology
|
June 20, 2012
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
Ling Cen, Brett L Carlson, Mark A Schroeder, et al.
Neuro-Oncology
|
March 13, 2013
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models
Ling Cen, Brett L Carlson, Jenny L Pokorny, et al.
Leukemia Research
|
August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Armin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 109) with videos related to
Sort By:
Page
of 11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma
Pavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2012
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts
Gaspar J Kitange, Ann C Mladek, Brett L Carlson, et al.
Journal of Neuro-Oncology
|
November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
Gaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
Molecular Cancer Therapeutics
|
January 29, 2009
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J Clarke, Evan A Mulligan, Patrick T Grogan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 4, 2015
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
Khoan Vu, Shivaprasad Manjappa, John F DiPersio, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 19, 2016
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
Ramzi Abboud, Jesse Keller, Michael Slade, et al.
Blood
|
March 12, 2020
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia, Miguel-Angel Perales, Mark A Schroeder, et al.
Neuro-Oncology
|
June 20, 2012
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
Ling Cen, Brett L Carlson, Mark A Schroeder, et al.
Neuro-Oncology
|
March 13, 2013
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models
Ling Cen, Brett L Carlson, Jenny L Pokorny, et al.
Leukemia Research
|
August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Armin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Page
of 11